CUV — Clinuvel Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- AU$381.23m
- AU$131.12m
- AU$94.02m
Annual cashflow statement for Clinuvel Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.466 | 2.75 | 8.19 | 7.47 | 10.2 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 39.9 | 36.9 | 37.1 | 41.1 | 36.9 |
| Capital Expenditures | -0.434 | -1.03 | -5.58 | -0.299 | -1.6 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -23.5 | -47.4 | -37.5 |
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.434 | -1.03 | -29 | -47.7 | -39.1 |
| Financing Cash Flow Items | 0 | 0 | — | -0.189 | -0.574 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1.5 | -2.24 | -3.57 | -2.94 | -2.75 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 38.8 | 35.3 | 3.31 | -7.18 | -6.63 |